Healthcare Industry News: Elekta
News Release - February 27, 2013
Elekta Focuses on Clinical Workflows with MOSAIQ Oncology Information Management System at HIMSS13 MeetingElekta to accept award for MOSAIQ top ranking in 2012 Best in KLAS Awards
ATLANTA and NEW ORLEANS, Feb. 27, 2013 -- (Healthcare Sales & Marketing Network) -- Acknowledging the importance of dedicated information management systems for radiation and medical oncology practices, Elekta will demonstrate the most recent version of its MOSAIQ® Oncology Information Management System (OIS) at the Healthcare Information and Management Systems Society's 2013 conference (HIMSS13), March 3-7, in New Orleans.
MOSAIQ is a comprehensive OIS that centralizes traditional radiation oncology, particle therapy and medical oncology patient data into a single user interface, accessible by multidisciplinary teams across multiple locations. MOSAIQ provides oncology staff access to the underlying clinical and administrative data, improving both clinical care and operational efficiency.
Visitors to Elekta booth #1511 will learn how MOSAIQ integrates with a diverse array of hospital systems, treatment devices and imaging systems, increasing accessibility to critical data anytime by remote users on various platforms. MOSAIQ captures the entire patient chart in a common database that users can customize, allowing radiation oncologists and medical oncologists to coordinate care for complex cases. In addition to fulfilling the needs of hospital-based centers, MOSAIQ provides functionality community cancer centers require in a comprehensive oncology information system, including clinical, administrative, and billing.
MOSAIQ is a scalable, flexible solution designed exclusively for oncology, and is well-suited for integration with enterprise EHRs. At HIMSS13, Elekta will showcase some of the latest MOSAIQ functionality designed to eliminate bottlenecks in clinical and administrative workflows, including:
- IQ Scripts™, an engine that can seamlessly automate tasks and establish consistent processes across the clinic
- eScribe merge fields, which allows encounters to be documented instantly and completely utilizing discrete data elements within the patient chart
- MOSAIQ Evaluate, a powerful review module integrated directly with the world's most widely-used OIS, designed to bring the radiation treatment plan to the care team
At a presentation during HIMSS, MOSAIQ will be recognized for its number one ranking in the recently released 2012 Best in KLAS Awards: Software & Services report. The report is a summary of performance data collected over the past 12 months and ranks the top overall vendors. In addition, MOSAIQ recently was ranked No. 1 in the KLAS Oncology IT Report, Pulling the Curtain Back.
"We can't think of a better event than HIMSS to showcase MOSAIQ to the healthcare IT leadership," says Todd Powell, Executive Vice President, Elekta Software. "We're confident that healthcare IT professionals will recognize that a best-of-breed oncology information system is an absolutely critical element to streamline clinical workflow."
Learn more at www.Elekta.com/MOSAIQ.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.Elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.